Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.